NCT05930561 - 4D-150 in Patients With Diabetic Macular Edema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 9, 2023

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2029

Conditions

Diabetic Macular EdemaDiabetic Retinopathy

Interventions

BIOLOGICAL

4D-150 IVT

4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept.

BIOLOGICAL

Aflibercept IVT

Commercially available Active Comparator

Trial Locations (6)

Erie Retina Research, Erie

Cumberland Valley Retina Consultants, Hagerstown

Piedmont Eye Center, Lynchburg

Austin Clinical Research, Austin

Verum Research, LLC, Eugene

Emanuelli Research and Development Center, Arecibo